BeOne Medicines (ONC)

Executive Summary

BeOne Medicines (BeiGene) is a global biotechnology company focused on the discovery, development, and commercialization of cancer therapies. With a strong portfolio including FDA-approved BRUKINSA® (zanubrutinib) and tislelizumab, the company has established a commercial presence in the US, China, and EU. Its pipeline encompasses over 10 clinical-stage programs targeting hematologic malignancies and solid tumors, with early-stage candidates such as BGB-16673 (BTK degrader), BG-89894 (MTAP-deleted solid tumors), and BG-60366 (EGFR-mutant NSCLC). The company's integrated manufacturing capabilities in China and the US support its global supply chain, while its robust research engine continues to generate novel molecules, including next-generation BTK inhibitors and CDK4 inhibitors. Despite recent commercial headwinds from biosimilar competition, BeOne's deep pipeline and international footprint position it for long-term growth. The company's conviction score of 75 reflects its solid foundation with approved products and a promising early-stage pipeline, tempered by the high risk of Phase 1 assets and competitive oncology landscape.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 data readout for BGB-15025 + tislelizumab in advanced solid tumors60% success
• Q2 2026Phase 1 safety data for BGB-45035 in healthy volunteers (autoimmune potential)70% success
• Q3 2026Potential tislelizumab label expansion or regulatory decision for first-line ESCC in EU/US65% success